Anzeige
Mehr »
Samstag, 02.05.2026 - Börsentäglich über 12.000 News
Erste Genehmigung für Tiefseebergbau seit 1980: Warum dieser Meilenstein für den nächsten Small-Cap-Akteur wichtig ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EGXK | ISIN: SE0020353928 | Ticker-Symbol: MB8
Tradegate
29.04.26 | 10:35
1,056 Euro
-1,86 % -0,020
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
MOBERG PHARMA AB Chart 1 Jahr
5-Tage-Chart
MOBERG PHARMA AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,0261,09030.04.
1,0581,09230.04.

Aktuelle News zur MOBERG PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
24.04.Moberg Pharma AB: Moberg Pharma and Karo Healthcare expand collaboration for MOB-015/Terclara to Australia, New Zealand, South Korea and Taiwan264STOCKHOLM, April 24, 2026. Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of the nail fungus treatment MOB-015 (Terclara®)...
► Artikel lesen
17.04.Notice of Annual General Meeting in Moberg Pharma AB (publ)2
13.03.MOBERG PHARMA AB: Additional terbinafine supplier approved2
17.02.Moberg Pharma AB Q4 Loss Declines-
MOBERG PHARMA Aktie jetzt für 0€ handeln
17.02.Moberg Pharma AB: Moberg Pharma Year-end report 2025173A BREAKTHROUGH YEAR WITH A CLEAR PATH TO EUROPE THE YEAR (JAN-DEC 2025) Net revenue SEK 13.5 million (9.8) EBITDA SEK -25.7 million (-23.5) Operating profit (EBIT) SEK -27.3 million (-324.8)...
► Artikel lesen
11.11.25Moberg Pharma AB: Moberg Pharma interim report January - September 2025198FURTHER SUCCESS FOR TERCLARA NINE-MONTH PERIOD (JAN-SEP 2025) Net revenue SEK 11.5 million (8.8) EBITDA SEK -18.7 million (-15.7) Operating profit (EBIT) SEK -19.9 million (-16.7) Profit for...
► Artikel lesen
05.11.25Moberg Pharma signs European licensing deal with Karo Healthcare15
05.11.25Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential426STOCKHOLM, Nov. 5, 2025 /PRNewswire/ -- Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of MOB-015...
► Artikel lesen
05.11.25Karo Healthcare enters an exclusive license agreement with Moberg Pharma for MOB-015 in Europe372STOCKHOLM, Nov. 5, 2025 /PRNewswire/ -- Karo Healthcare AB ("Karo") has entered an exclusive licensing agreement with Moberg Pharma AB ("Moberg Pharma") regarding the commercialisation...
► Artikel lesen
05.11.25Moberg Pharma and Karo Healthcare enter exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential2
29.09.25Moberg Pharma AB: Bulletin from Moberg Pharma's Extraordinary General Meeting held on 29 September 2025218STOCKHOLM, September 29th, 2025. Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") today held an Extraordinary General Meeting. The Extraordinary General Meeting resolved in accordance with...
► Artikel lesen
12.08.25Moberg Pharma AB: Interim report January - June 2025290TERCLARA MARKET LEADER ALSO IN NORWAY SIX-MONTH PERIOD (JAN-JUN 2025) • Net revenue SEK 7.5 million (4.9) • EBITDA SEK -13.1 million (-12.7) • Operating profit (EBIT) SEK -13.9 million (-13.4)...
► Artikel lesen
13.05.25Moberg Pharma AB: Moberg Pharma interim report January - March 2025218TERCLARA NOW ALSO AVAILABLE IN NORWAY FIRST QUARTER (JAN-MAR 2025) Net revenue SEK 3.9 million (0.8) EBITDA SEK -3.7 million (-7.6) Operating profit (EBIT) SEK -4.1 million (-7.9) Profit for...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1